Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:30 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pazopanib or Pemetrexed and Crizotinib in Advanced Cancer
NCT01548144 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2021-09-13 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI request” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MET within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2022-09-02Results posted on the registry: National Cancer Institute (NCI), Cabozantinib S-malate + Crizotinib (NCT02761057)
- 2022-07-06Results posted on the registry: National Cancer Institute (NCI), Brentuximab Vedotin + Crizotinib (NCT01979536)
- 2022-05-24Phase 3 first posted: Janssen Research & Development, LLC, Lazertinib + Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF) (NCT05388669)
- 2022-04-26Results posted on the registry: Bristol-Myers Squibb, Nivolumab + Cabozantinib (NCT03141177)
- 2022-03-02Phase 3 first posted: AstraZeneca, Savolitinib + Osimertinib (NCT05261399)
- 2022-02-09Results posted on the registry: Pfizer, Avelumab + PF-06463922 (NCT02584634)
- 2021-10-26Phase 3 first posted: National Cancer Institute (NCI), Avelumab + Cabozantinib S-malate (NCT05092958)
- 2021-09-16Results posted on the registry: National Cancer Institute (NCI), Cabozantinib (NCT01755195)
- 2021-09-13Phase 3 first posted: AstraZeneca, savolitinib + durvalumab (NCT05043090)
- 2021-08-20Phase 3 first posted: Hutchison Medipharma Limited, Savolitinib + Osimertinib + Pemetrexed + Cisplatin /Carboplatin (NCT05015608)
- 2021-08-18Phase 3 first posted: Hutchmed, Savolitinib + Placebo (NCT05009836)
- 2021-08-03Phase 3 first posted: Janssen Research & Development, LLC, Lazertinib + Amivantamab (NCT04988295)
- 2021-06-16Phase 3 first posted: AbbVie, Telisotuzumab Vedotin + Docetaxel (NCT04928846)
- 2021-06-11Phase 3 first posted: Hutchison Medipharma Limited, Savolitinib (NCT04923945)
- 2021-04-01Results posted on the registry: Pfizer, Lorlatinib + Crizotinib (NCT03052608)
- 2021-03-25Phase 3 first posted: Novartis Pharmaceuticals, Capmatinib + Osimertinib (NCT04816214)
- 2021-02-18Phase 3 first posted: Hoffmann-La Roche, Pralsetinib + Cabozantinib (NCT04760288)
- 2020-11-17Phase 3 first posted: Qilu Pharmaceutical Co., Ltd., WX-0593 Tablets + crizotinib (NCT04632758)
- 2020-10-27Phase 3 first posted: Hoffmann-La Roche, Entrectinib + Crizotinib (NCT04603807)
- 2020-10-14Phase 3 first posted: Merck Sharp & Dohme LLC, Belzutifan + Lenvatinib (NCT04586231)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision